STTK Shattuck Labs, Inc.

NEUTRAL Impact: 3/10 8-K
Horizon immediate Filed Jun 2, 2026 Processed 3d ago SEC 0001193125-26-253784
8-K context-dependent: Items 5.02

Price Chart

Loading chart...

Executive Summary

Shattuck Labs held its 2026 Annual Meeting on May 28, 2026. Stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan, increasing the share reserve by 1,691,082 shares and extending the plan term to March 23, 2036. All director nominees were elected, KPMG was ratified as auditor, and the advisory vote on executive compensation passed with 92.0% support. The filing is a routine post-meeting 8-K with no material financial or operational news.

Actionable Insight

Routine annual meeting 8-K with no trading catalyst. The 19.8% vote against the equity plan amendment is notable but non-binding and does not affect the plan's adoption. Monitor for any future equity grants under the expanded share reserve, but no immediate action required.

Key Facts

  • Stockholders approved amendment to 2020 Equity Incentive Plan, increasing shares available by 1,691,082 shares
  • Plan term extended to March 23, 2036; evergreen provision set at 4% of outstanding capital stock annually through 2030
  • All three Class III director nominees elected: Taylor Schreiber (94.7% for), Helen Boudreau (92.4% for), Clay Siegall (93.0% for)
  • KPMG ratified as independent auditor with 99.98% of votes cast in favor
  • Advisory vote on executive compensation passed with 92.0% support; company will hold future say-on-pay votes annually
  • Proposal 5 (equity plan amendment) passed with 80.2% of votes cast in favor, with 19.8% against

Financial Impact

No financial impact. The equity plan amendment increases potential dilution by 1,691,082 shares (approximately 2.2% of the 75.6M shares outstanding as of record date), but no immediate issuance or cash impact.

dilution

Risk Factors

  • Increased potential dilution from expanded equity plan (up to ~2.2% of outstanding shares annually through 2030)
  • 19.8% vote against equity plan amendment suggests some shareholder discontent with compensation structure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-253784
Document: d149753d8k.htm0001193125-26-253784
Document: 0001193125-26-253784-index-headers.html0001193125-26-253784
Document: 0001193125-26-253784-index.html0001193125-26-253784
Document: 0001193125-26-253784.txt0001193125-26-253784
8 reports for STTK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for STTK — sortable, filterable
Type Now
Jun 2, 2026
3d ago
8-K
NEUTRAL ★ 3/10
awaiting T+5
May 15, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$6.26 $6.10▼ −2.56%▼ −3.52%$4.58 (−26.84%)
May 12, 2026
24d ago
Insider Cluster
NEUTRAL ★ 3/10
$6.62 $5.79▼ −12.54%▼ −11.94%$4.58 (−30.82%)
May 7, 2026
29d ago
8-K
NEUTRAL ★ 3/10
$6.26 $6.75▲ +7.83%▲ +6.32%$4.58 (−26.84%)
May 7, 2026
29d ago
Press Release
BULLISH ★ 5/10
$6.26 $6.75▲ +7.83%▲ +6.32%$4.58 (−26.84%)
Apr 8, 2026
8w ago
DEFA14A
NEUTRAL ★ 3/10
$7.02 $7.17▲ +2.14%▼ −1.38%$4.58 (−34.76%)
Mar 5, 2026
13w ago
8-K
NEUTRAL ★ 5/10
$5.10 $6.13▲ +20.20%▲ +22.43%$4.58 (−10.20%)
Mar 5, 2026
13w ago
Press Release
NEUTRAL ★ 5/10
$5.10 $6.13▲ +20.20%▲ +22.43%$4.58 (−10.20%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (64h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access